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OBJECTIVE— Chromium treatment has been reported to improve glycemic control in pa-
tients with type 2 diabetes. However, concern exists about the possible toxic effects of chromium
picolinate. The aim of this study was to determine the effect of chromium treatment in the form
of chromium yeast on glycemic control in a Western population of patients with type 2 diabetes
who were being treated with oral hypoglycemic agents.
RESEARCH DESIGN AND METHODS— In this 6-month, double-blind study, pa-
tients with moderate glycemic control, being treated with oral hypoglycemic agents, were ran-
domly assigned to receive either a placebo or treatment with 400 g of chromium daily in the
form of chromium yeast. The primary efficacy parameter was a change in A1C. Secondary end
points were changes in lipid profile, BMI, blood pressure, body fat, and insulin resistance.
RESULTS— No differences were found for the change in A1C between the intervention and
placebo groups, nor were any differences found between the groups for the secondary end
points.
CONCLUSIONS— There is no evidence that chromium in the form of chromium yeast is
effective in improving glycemic control in Western patients with type 2 diabetes who are taking
oral hypoglycemic agents.
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T ype 2 diabetes is a chronic, progres-sive illness that causes considerablemorbidity and premature mortality
(1,2). The worldwide prevalence of type 2
diabetes is high and is increasing steadily
(3). The majority of patients are insulin
resistant (4). Although these patients may
be treated with well-established hypogly-
cemic agents, studying alternative treat-
ment options directed toward improving
insulin sensitivity is important.
For many decades, we have known
that chromium plays a role in glucose me-
tabolism, and, as early as 1957, it was al-
ready being referred to as “a glucose
tolerance factor” (5). In vitro and animal
studies have shown that chromium im-
proves insulin resistance (6,7). One of the
intracellular proteins that influences the
insulin receptor is the oligopeptide
apolipoprotein low–molecular weight
chromium-binding substance (Apo-
chromomodulin) (7). This peptide has
the ability to increase tyrosine kinase
activity eightfold, depending on the chro-
mium concentration (8), thus strengthen-
ing the idea that chromium plays an
influential role in glucose metabolism (5).
The largest study (n  180) to date
investigating the effect of chromium in
patients with type 2 diabetes was pub-
lished by Anderson et al. (9). They found
that the A1C of Chinese patients treated
with 1,000g of chromium in the form of
chromium picolinate decreased almost 2
percentage points compared with a pla-
cebo group after 4 months. However, two
systematic reviews that addressed the
effects of chromium on glycemic con-
trol concluded that, on the basis of the
currently available data, the effects of
chromium on glycemic control are incon-
clusive (10,11). Randomized studies with
results on glucose, insulin, and/or A1C
were collected by Althuis et al. (10) in
their review. Reasons for the inconclusive
findings are that too few trials in patients
with diabetes have been conducted to al-
low conclusive findings (three trials with
a total of 38 subjects).
Furthermore, in recent years, the
safety of chromium supplements has been
called into question because of mixed re-
sults in studies investigating the mutage-
nicity of chromium picolinate in vitro
(12–14). Although toxic effects were re-
ported in neither the systematic reviews
(10,11) nor in the study of Anderson et al.
(9), chromium picolinate was banned by
the Food Standards Agency until Decem-
ber 2004 (15). This meant that investiga-
tions into the effects of chromium
compounds on type 2 diabetes had to in-
volve compounds other than chromium
picolinate. Some studies, in which the ef-
fects of chromium-enriched yeast in non-
diabetic patients were investigated,
showed mixed results (16–19). Bahijri et
al. (20) investigated the effects of different
forms of chromium with a double-blind
cross-over design and concluded that
fasting glucose in patients with type 2 di-
abetes improved after 8 weeks of daily di-
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etary supplementation with brewer’s
yeast containing 23.2 g of chromium.
We performed a double-blind, random-
ized, placebo-controlled study to investi-
gate the effects of chromium in the form
of chromium yeast (Saccharomyces cerevi-
siae) on glycemic control, insulin resis-
tance, and factors associated with the
metabolic syndrome in subjects with type
2 diabetes in a Western population.
RESEARCH DESIGN AND
METHODS— Using our local Diabe-
tes Electronic Management System, we
selected patients with type 2 diabetes
from a village in the Zwolle region in the
northern Netherlands who met the fol-
lowing eligibility criteria: A1C 7–8.5% as
measured during their latest visit, treat-
ment with oral hypoglycemic agents only,
no change in treatment during the pre-
ceding 3 months, creatinine150mol/l
for men and 120 mol/l for women,
creatinine clearance 50 ml/min, and
alanine aminotransferase (ALT) 90
units/l. Exclusion criteria included preg-
nancy (including patients who were try-
ing to conceive), known allergy or
intolerance to yeast, and current use of
chromium supplements.
In five general practices in a village in
the region of Zwolle, 63 patients had a
A1C of 7–8.5%, with a mean  SD of
7.7 0.44%. To test our hypothesis that
chromium causes a 0.5% absolute reduc-
tion in A1C (primary outcome measure),
with a power of 95% and  of 0.05, two-
tailed; a sample size of 22 per group
would be required (assuming a correla-
tion of 0.5 between pretest and posttest).
To compensate for nonevaluable patients,
we planned to enroll 30 patients per
group. The secondary outcome measures
were changes in lipid profile, body
weight, blood pressure, body fat, and in-
sulin resistance. After the potential partic-
ipants had been informed about the study
by their attending general practitioner
and by mail, the researchers contacted
each candidate patient by telephone, at
home, and asked whether they would be
willing to participate. Patients were in-
cluded after written informed consent
was obtained. This study was approved
by the Medical Ethics Committee of the
Isala Clinics, Zwolle, Netherlands.
The study was carried out in a general
practice in the Zwolle region. One pa-
tient, who initially had agreed to partici-
pate in the study, later refused to
participate. Two patients were not ran-
domly assigned because they did not meet
the eligibility criteria (both creatinine
clearances 50 ml/min). Figure 1 shows
the Consolidated Standards of Reporting
Trials (CONSORT) flow diagram (21). A
total of 57 patients were randomly as-
signed into the following two groups: one
group was given two placebo tablets twice
daily (n  28) and one group received
two tablets of 100 g of chromium yeast
twice daily (n  29); 56 patients com-
pleted the study, which lasted 6 months.
The study participants were asked not
to make any lifestyle changes. No changes
were made in cholesterol-reducing and
blood pressure–lowering agents during the
study. Adjustments were made to the oral
hypoglycemic agents only when patients
developed complaints relating to hypogly-
cemia or symptomatic hyperglycemia.
All of the study medications, includ-
ing the placebo, were supplied by Pharma
Nord (Sadelmagervej, Vejle, Denmark)
and were indistinguishable from each
other. The researchers did not know into
which group the patients had been ran-
domly assigned nor did the patients. The
drug packages were labeled with a ran-
domization code by the pharmacy. No re-
strictions were used. The code was only
revealed to the researchers once recruit-
ment, data collection, and laboratory
analyses were complete. The patients
were instructed to take two tablets with
breakfast and two with the evening meal.
If the patients developed any side effects,
they were requested to stop taking the
study medication for 1 week and then to
resume.
At baseline, we recorded the duration
of the type 2 diabetes and any medica-
tion(s) the patients were taking. The pa-
tients were weighed with clothing on but
without shoes. Height was measured
without shoes. Blood pressure was mea-
sured after the patient had been sitting for
a minimum of 5 min. Blood pressure was
measured twice on each arm with a min-
imal interval of 15 s between successive
measurements. The mean for each arm
was calculated. When there was an inter-
arm difference of 10 mmHg between
the systolic and/or diastolic blood pres-
sures, the follow-up measurements were
continued on the arm with the higher
blood pressure. When the difference was
less, an arbitrary arm was taken for the
next measurements. The validated auto-
mated blood pressure device Omron
HEM-711 was used (22). We used the
validated Omron HBF-306-E to estimate
the patients’ body fat percentages and
used the mean of two consecutive mea-
surements (23).
Serum creatinine, hemoglobin,
ALT, A1C, fasting plasma glucose, se-
rum total cholesterol, LDL, HDL, tri-
glycerides, and fasting insulin were
measured according to the standard
hospital procedures of the Isala clinics.
A 24-h urine sample was collected, and
volume, creatinine, and albumin were
measured. We used the homeostasis
model assessment to estimate insulin
resistance (HOMA-IR) (24).
Hemoglobin and A1C were measured
at 3 months. At 6 months, all of the as-
Figure 1—CONSORT flow diagram.
Kleefstra and Associates
DIABETES CARE, VOLUME 30, NUMBER 5, MAY 2007 1093
sessments done at baseline were repeated
with the exception of height. Any re-
ported side effects were recorded at 3 and
at 6 months.
At 1 month (telephone contact), 3
months, and 6 months, we asked patients
how they were faring with the study med-
ication to check and stimulate compli-
ance. At 3 and 6 months, all remaining
tablets were collected and counted. At 6
months, we asked the patients to guess
into which group they had been assigned.
If the study was successfully blinded, the
ability of participants to accurately guess
their group assignment should not be bet-
ter than chance.
In the intention-to-protocol analyses,
patients were excluded when the pill
count was 90%. Furthermore, patients
were excluded from intention-to-
protocol analyses for glycemic, blood
pressure, and/or lipid parameters if any




A CONSORT diagram was used for this
study as presented in Fig. 1 (21). The
Mann-Whitney U test was used for non-
normal variables, and the 2 test was ap-
plied to categorical variables. To evaluate
differences in target variables over time
and between the groups, we used the gen-
eral linear model (GLM). For variables
measured at baseline, after 3 and after 6
months the GLM repeated measures with
the Greenhouse-Geiser test was used; the
three variables were used as within-
subject variables and randomization to
chromium or placebo was used as a be-
tween-subjects factor. For variables mea-
sured at baseline and after 6 months, we
used the GLM univariate with change in
variable over 6 months as the dependent
variable and randomization to chromium
or placebo as the fixed factor. In both the
GLM repeated measures and the univari-
ate, the baseline value was set as the co-
variate. SPSS software (version 11.0;
SPSS, Chicago, IL) was used for all the
analyses.
RESULTS— Eligible participants were
recruited in August 2004. Of the 57 pa-
tients who were randomly assigned, 1 pa-
tient did not complete the study (Fig. 1)
because of a cerebrovascular accident (in-
tervention group).
Two patients experienced adverse ef-
fects. One patient in the intervention
group complained of nausea, which dis-
appeared when the medication was
stopped and reappeared after restart. One
patient in the control group complained
of nonspecific stomach problems, which
disappeared during cessation of medica-
tion and reappeared after restart.
Table 1 shows the baseline character-
istics of the patients. Random assignment
was successful, as two comparable groups
resulted for most variables. Diabetes du-
ration, fasting plasma glucose, and
HOMA-IR appear to be longer or higher,
respectively, in the chromium group.
The percentage of medication used
was calculated and compared with the ex-
pected percentage in subjects with 100%
compliance (25,26). The mean percent-
age in the chromium group was 93.1 (me-
dian [25–75%] 95.5 [91.1–98.2]), and
the mean percentage in the placebo group
was 94.4 (97.3 [92.3–98.1]). This differ-
ence was not significant (P  0.606).
Three patients in the placebo group and
four in the chromium group did not reach
a minimum pill count of 90%. No expla-
nation for this stoppage was found for two
patients (one in each group). For the
other patients, the reasons were stopping
during a hospital stay (n  2), stopping
during a flu period (n  2), and taking
one tablet twice daily for a brief time by
mistake (n  1). Two patients (one in
each group) started insulin therapy dur-
ing the study. The different intention-to-
protocol analyses did not result in any
significant difference between the placebo
and chromium-treated groups (data not
shown).
Table 2 shows the changes in the vari-
ables per intervention after 6 months. No
significant differences were found over
time between the two groups for fasting
plasma glucose levels, A1C, blood pres-
sure, body fat percentage, weight, lipid
profile, and insulin resistance. Also after 3
months, there were no significant differ-
ence in A1C between the chromium and
placebo groups (0.03% [95% CI0.19 to
0.25]). After 3 and 6 months, hemoglobin
remained the same in both groups.
Twenty-five of the 56 patients (45%)
had no idea into which group they had
been randomly assigned; 17 patients, 8 of
whom were correct, thought that they had
been randomly assigned into the chro-
mium treatment group; and 8 of 14 pa-
tients correctly guessed that they had
been randomly assigned into the placebo
group. These results are not higher than
would be obtained by chance (P 
0.591).
CONCLUSIONS— Chromium yeast
treatment had no effect on A1C, weight,
blood pressure, insulin resistance, body
fat, and lipid profile compared with pla-
Table 1—Baseline characteristics per intervention group
Placebo Chromium
n 28 29
Sex (male) 17 (49) 18 (51)
Age (years) 66  8.6 68  8.2
Diabetes duration (years) 4.5 (2.0,9.5) 6.0 (4.0,10.0)
Body weight (kg) 87  17 88  20
BMI (kg/m2) 30  5.6 30  5.9
Body fat (%) 34  7.7 34  7.8
Systolic blood pressure (mmHg) 153  19 151  20
Diastolic blood pressure (mmHg) 88  10 88  13
Hemoglobin (mmol/l) 8.8  0.7 8.7  0.8
ALT (units/l) 30  16 34  18
Creatinine (mol/l) 97  16 95  18
Creatinine clearance (ml/min) 88  24 97  36
Albuminuria (mg/24 h) 4.44 (3.00,29.13) 4.9 (3.00,17.00)
Fasting plasma glucose (mmol/l) 8.0  1.8 8.7  2.3
A1C (%) 7.01  0.50 6.92  0.67
Total cholesterol (mmol/l) 4.60  1.34 4.46  1.15
Cholesterol-to-HDL ratio 3.70  1.25 3.68  1.14
Triglycerides (mmol/l) 1.46 (0.91,2.34) 1.70 (1.11,2.10)
HDL (mmol/l) 1.31  0.38 1.28  0.36
LDL (mmol/l) 2.50  0.95 2.42  1.01
HOMA-IR (units) 3.8 (2.7,5.5) 5.8 (2.7,8.9)
Data are means  SD, n (% of known data), or median (P25,P75).
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cebo in this 6-month, double-blinded,
randomized, controlled trial, in patients
with moderately controlled type 2 diabe-
tes in a Western society. Two patients
stopped the study medication because of
adverse effects, one in the placebo group
because of stomach problems and one in
the chromium yeast group because of
nausea.
The results of this study agree with
the results of two systematic reviews that
examined the effects of chromium on gly-
cemic control (10,11). After the publica-
tion of the review conducted by Althuis et
al. (10), results of five randomized con-
trolled trials examining the effects of
chromium on glycemic control were pub-
lished. The first study was conducted in
Indian patients with type 2 diabetes (27).
It reported that A1C worsened in the pla-
cebo group compared with the group
treated with 400 g of chromium picoli-
nate (	0.7%). A1C remained stable in the
treatment group (27). In the second
study, in patients with impaired glucose
tolerance, treatment with 800 g of chro-
mium picolinate was not found to have
any beneficial effect on glycemic control
(28). The third study was our previous
randomized controlled trial examining
the effects of treatment with 500 and
1,000 g of chromium picolinate in pa-
tients with poorly controlled insulin-
treated type 2 diabetes. No improvement
in glycemic control was seen after 6
months of therapy (29). In the fourth
study, in patients with poorly controlled
diabetes treated with sulfonylureas, a de-
crease of 0.7 percentage point was found
in the group treated with 1,000 g of
chromium picolinate compared with pla-
cebo after 24 weeks of therapy (30). In the
fifth study, in Czech patients with type 2
diabetes, a lower fasting glucose level was
seen in the group treated with 400 g of
chromium in the form of chromium yeast
after 12 weeks; however, no change in
A1C was found (19).
A limitation of our study is that we
selected patients on the basis of an A1C
measurement during a previous visit to
the local general practitioner or practice
nurse. Although no hypoglycemic medi-
cation was changed in the 3 months pre-
ceding this study, it is notable that the
baseline A1C values in both groups are
relatively low. Also, the SD for A1C was
larger than that in our power calculation.
However, with a SD of 0.59 (the SD for
change in A1C was 0.57) in our study, it
would still leave a high power of 93% to
detect a 0.5 difference in A1C in 28 sub-
jects per group. Another limitation was
the inability to select patients on the basis
of chromium deficiency, as there is still no
real standard for chromium status (20).
As a result, it is possible that we gave
chromium to subjects with a (relatively)
normal chromium status. Furthermore,
the duration of this study was only 6
months.
There is no evidence that chromium
therapy in a Western population with di-
abetes who are being treated with oral hy-
poglycemic agents will improve glycemic
regulation or parameters associated with
the insulin resistance syndrome, apart
from one small study in patients with
poorly controlled type 2 diabetes, who
were taking sulfonylureas (30). There-
fore, there seems to be no reason for rec-
ommend the use of chromium as a
standard part of diabetes therapy (31).
Acknowledgments— We thank the Langer-
hans Foundation, the Medical Research Foun-
dation, and Pharma Nord for their financial
support. Pharma Nord did not have any role in
study design; in the collection, analysis, and
interpretation of data; or in the decision to
submit the article for publication.
We thank all the treating general practitio-
ners and practice nurses (Rita Ebbink and Els
Zoon) who cooperated fully and provided fa-
cilities for this study. Furthermore, we thank
Marike van der Saag and Rein Dragt of the
laboratory of the Isala clinics for all their efforts
(one time traveling with 20 containers of 24-h
collected urine through 50 cm of snow). Also,
we thank Klaas Groenier for assisting with the
statistical analysis.
References
1. Amos AF, McCarty DJ, Zimmet P: The ris-
ing global burden of diabetes and its com-
plications: estimates and projections to
the year 2010. Diabet Med 14:S7–S85,
1997
2. Kannel WB, McGee DL: Diabetes and car-
diovascular disease: the Framingham
study. JAMA 241:2035–2038, 1979
3. King H, Aubert RE, Herman WH: Global
burden of diabetes, 1995–2025: preva-
lence, numerical estimates, and projec-
tions. Diabetes Care 21:1414–1431, 1998
4. Lakka HM, Laaksonen DE, Lakka TA, Ni-
skanen LK, Kumpusalo E, Tuomilehto J,
Salonen JT: The metabolic syndrome and
total and cardiovascular disease mortality
in middle-aged men. JAMA 288:2709–
2716, 2002




400 g vs. placebo P value
n 28 28
Fasting plasma glucose (mmol/l) 0.7  1.7 0.9  2.3 0.5 (0.5 to 1.5) 0.311
A1C (%) 0.26  0.47 0.51  0.64 0.24 (0.06 to 0.54) 0.161
Systolic blood pressure (mmHg) 9  15 6  17 3 (12 to 6) 0.490
Diastolic blood pressure (mmHg) 3  8 0  9 3 (7 to 2) 0.195
Body fat (%) 0.2  2.6 0.1  1.4 0.3 (1.5 to 0.8) 0.569
BMI (kg/m2) 0.4  0.9 0.1  0.8 0.3 (0.8 to 0.2) 0.226
Total cholesterol (mmol/l) 0.23  0.64 0.46  0.42 0.23 (0.07 to 0.52) 0.128
Cholesterol-to-HDL ratio 0.11  0.52 0.11  0.64 0.01 (0.29 to 0.28) 0.964
Triglycerides (mmol/l) 0.13  0.68 0.03  0.49 0.10 (0.42 to 0.22) 0.526
HDL (mmol/l) 0.11  0.15 0.14  0.18 0.03 (0.06 to 0.12) 0.536
LDL (mmol/l) 0.06  0.63 0.31  0.4 0.25 (0.04 to 0.52) 0.087
HOMA-IR (units) 1.9  4.7 0.4  4.7 1.3 (3.7 to 1.1) 0.293
Data are means  SD within the group and mean differences between groups (95% CI).
Kleefstra and Associates
DIABETES CARE, VOLUME 30, NUMBER 5, MAY 2007 1095
5. Schwarz K, Mertz W: A glucose tolerance
factor and its differentiation from factor 3.
Arch Biochem Biophys 72:515–518, 1957
6. Shindea UA, Sharma G, Xu YJ, Dhalla NS,
Goyal RK: Insulin sensitising action of
chromium picolinate in various experi-
mental models of diabetes mellitus. J
Trace Elem Med Biol 18:23–32, 2004
7. Davis CM, Vincent JB: Chromium oli-
gopeptide activates insulin receptor ty-
rosine kinase activity. Biochemistry 36:
4382–4385, 1997
8. Sun Y, Ramirez J, Woski SA, Vincent JB:
The binding of trivalent chromium to
low-molecular-weight chromium-bind-
ing substance (LMWCr) and the transfer
of chromium from transferrin and chro-
mium picolinate to LMWCr. J Biol Inorg
Chem 5:129–136, 2000
9. Anderson RA, Cheng N, Bryden NA, Po-
lansky MM, Chi J, Feng J: Elevated intakes
of supplemental chromium improve glu-
cose and insulin variables in individuals
with type 2 diabetes. Diabetes 46:1786–
1791, 1997
10. Althuis MD, Jordan NE, Ludington EA,
Wittes JT: Glucose and insulin responses
to dietary chromium supplements: a
meta-analysis. Am J Clin Nutr 76:148–
155, 2002
11. Yeh GY, Eisenberg DM, Kaptchuk TJ,
Phillips RS: Systematic review of herbs
and dietary supplements for glycemic
control in diabetes. Diabetes Care 26:
1277–1294, 2003
12. Manygoats KR, Yazzie M, Stearns DM:
Ultrastructural damage in chromium
picolinate-treated cells: a TEM study:
transmission electron microscopy. J Biol
Inorg Chem 7:791–798, 2002
13. Stearns DM, Silveira SM, Wolf KK, Luke
AM: Chromium(III) tris(picolinate) is
mutagenic at the hypoxanthine (guanine)
phosphoribosyltransferase locus in Chi-
nese hamster ovary cells. Mutat Res 15:
135–142, 2002
14. Slesinski RS, Clarke JJ, San RH, Gudi R:
Lack of mutagenicity of chromium pico-
linate in the hypoxanthine phosphoribo-
syltransferase gene mutation assay in
Chinese hamster ovary cells. Mutat Res
585:86–95, 2005
15. Agency revises chromium picolinate ad-
vice [article online], 2004. Available
from http://www.food.gov.uk/news/
newsarchive/2004/dec/chromiumupdate.
Accessed 2 October 2006
16. Li YC: Effects of brewer’s yeast on glucose
tolerance and serum lipids in Chinese
adults. Biol Trace Elem Res 41:341–347,
1994
17. Offenbacher EG, Rinko CJ, Pi-Sunyer FX:
The effects of inorganic chromium and
brewer’s yeast on glucose tolerance,
plasma lipids, and plasma chromium in
elderly subjects. Am J Clin Nutr 42:454–
461, 1985
18. Offenbacher EG, Pi-Sunyer FX: Beneficial
effect of chromium-rich yeast on glucose
tolerance and blood lipids in elderly sub-
jects. Diabetes 29:919–925, 1980
19. Racek J, Trefil L, Rajdl D, Mudrova V,
Hunter D, Senft V: Influence of chromi-
um-enriched yeast on blood glucose and
insulin variables, blood lipids, and mark-
ers of oxidative stress in subjects with type
2 diabetes mellitus. Biol Trace Elem Res
109:215–230, 2006
20. Bahijri SM, Mufti AM: Beneficial effects of
chromium in people with type 2 diabetes,
and urinary chromium response to glu-
cose load as a possible indicator of status.
Biol Trace Elem Res 85:97–109, 2002
21. Moher D, Schulz KF, Altman DG: The
CONSORT statement: revised recom-
mendations for improving the quality of
reports of parallel-group randomised tri-
als. Lancet 357:1191–1194, 2001
22. El Assaad MA, Topouchian JA, Asmar RG:
Evaluation of two devices for self-mea-
surement of blood pressure according to
the international protocol: the Omron
M5-I and the Omron 705IT. Blood Press
Monit 8:127–133, 2003
23. Deurenberg P, Andreoli A, Borg P, Kuk-
konen-Harjula K, de Lorenzo A, van
Marken Lichtenbelt WD, Testolin G, Vi-
gano R, Vollaard N: The validity of pre-
dicted body fat percentage from body
mass index and from impedance in sam-
ples of five European populations. Eur
J Clin Nutr 55:973–979, 2001
24. Asplund J, Danielson M, Ohman P: Pa-
tients compliance in hypertension—the
importance of number of tablets. Br J Clin
Pharmacol 17:547–552, 1984
25. Lebovits AH, Strain JJ, Schleifer SJ,
Tanaka JS, Bhardwaj S Messe MR: Patient
non-compliance with self-administered
chemotherapy. Cancer 65:17–22, 1990
26. Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF, Turner RC: Ho-
meostasis model assessment: insulin re-
sistance and 
-cell function from fasting
plasma glucose and insulin concentra-
tions in man. Diabetologia 28:412–419,
1985
27. Ghosh D, Bhattacharya B, Mukherjee B,
Manna B, Sinha M, Chowdhury J,
Chowdhury S: Role of chromium supple-
mentation in Indians with type 2 diabetes
mellitus. J Nutr Biochem 13:690–697,
2002
28. Gunton JE, Cheung NW, Hitchman R,
Hams G, O’Sullivan C, Foster-Powell K,
McElduff A: Chromium supplementation
does not improve glucose tolerance, insu-
lin sensitivity, or lipid profile: a random-
ized, placebo-controlled, double-blind
trial of supplementation in subjects with
impaired glucose tolerance. Diabetes Care
28:712–713, 2005
29. Kleefstra N, Houweling ST, Jansman FG,
Groenier KH, Gans RO, Meyboom-de
Jong B, Bakker SJ, Bilo HJ: Chromium
treatment has no effect in patients with
poorly controlled, insulin-treated type 2
diabetes mellitus in a Western popula-
tion: a randomized, double blind, place-
bo-controlled trial. Diabetes Care 29:521–
525, 2006
30. Martin J, Wang ZQ, Zhang XH, Wachtel
D, Volaufova J, Matthews DE, Cefalu WT:
Chromium picolinate supplementation
attenuates body weight gain and increases
insulin sensitivity in subjects with type 2
diabetes. Diabetes Care 29:1826–1832,
2006
31. Kleefstra N, Bilo HJ, Bakker SJ, Houwel-
ing ST: [Chromium and insulin resis-
tance]. Ned Tijdschr Geneeskd 148:217–
220, 2004 (in Dutch)
Chromium and diabetes
1096 DIABETES CARE, VOLUME 30, NUMBER 5, MAY 2007
